Godavari Pharma Sales Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 31-12-2024
- Paid Up Capital ₹ 0.10 M
as on 31-12-2024
- Company Age 5 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 9.00 M
as on 31-12-2024
- Revenue 20.22%
(FY 2022)
- Profit 16.22%
(FY 2022)
- Ebitda 11.31%
(FY 2022)
- Net Worth 61.96%
(FY 2022)
- Total Assets 20.04%
(FY 2022)
About Godavari Pharma Sales
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company has closed loans amounting to ₹9.00 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Madhavi Aurangabadkar, Rahul Aurangabadkar, Gopal Aurangabadkar, and One other member serve as directors at the Company.
- CIN/LLPIN
U24239PN2019PTC183809
- Company No.
183809
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Apr 2019
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Ratnagiri, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Godavari Pharma Sales?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Madhavi Aurangabadkar  | Director | 29-Apr-2019 | Current |
| Rahul Aurangabadkar | Director | 29-Apr-2019 | Current |
| Gopal Aurangabadkar | Director | 29-Apr-2019 | Current |
| Shraddha Aurangabadkar | Director | 30-Jul-2019 | Current |
Financial Performance of Godavari Pharma Sales.
Godavari Pharma Sales Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 20.22% increase. The company also saw a substantial improvement in profitability, with a 16.22% increase in profit. The company's net worth Soared by an impressive increase of 61.96%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Godavari Pharma Sales?
In 2022, Godavari Pharma Sales had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
₹0
₹9.00 M
Charges Breakdown by Lending Institutions
- State Bank Of India : 0.90 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 06 Jun 2019 | State Bank Of India | ₹9.00 M | Satisfied |
How Many Employees Work at Godavari Pharma Sales?
Godavari Pharma Sales has a workforce of 15 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Godavari Pharma Sales, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Godavari Pharma Sales's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.